High Q Technologies is leveraging a quantum-enabled electron paramagnetic resonance (EPR) platform to enhance drug discovery for Alzheimer's disease and other neurodegenerative disorders. The technology maps protein motion in greater detail, potentially revealing new therapeutic targets. The company's approach was highlighted in a recent Insider Brief article.
According to the company, the EPR platform uses quantum sensing to detect subtle changes in protein dynamics, which are often linked to disease progression. This could help researchers identify compounds that stabilize or correct protein misfolding, a hallmark of Alzheimer's. No specific clinical trial data or partnerships were disclosed in the available information.
High Q Technologies has not yet published peer-reviewed results on this specific application, but the platform builds on established EPR techniques used in structural biology. The company is based in the United States and focuses on quantum-enabled tools for biomedical research.
